Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Mar 18, 2015
Sangamo BioSciences Announces Participation In The 3rd Annual Regen Med Investor Day Meeting In New York

Mar 9, 2015
Sangamo BioSciences CEO To Present State Of The Industry Address At Alliance For Regenerative Medicine's Advanced Therapies Summit


Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
14.91
Change:
- 0.12
Day High:
15.25
Day Low:
14.41
Volume:
921,900
4:00 PM ET on Mar 26, 2015

Shareholder Tools